Finance

Lists
1SXP:ETR
SCHOTT Pharma AG & Co KgaA
€21,70
-0,69%
(-0,15) 1D
6 Nov., 12:31:19 GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1SXP...
Open
€21,95
High
€21,95
Low
€21,50
Mkt. cap
3,27 mjd
Avg. vol.
81,64 k
Volume
11,46 k
Dividend
0,83%
Quarterly dividend
€0,05
Ex-dividend date
04 Feb. 2026
P/E ratio
23,78
52-wk high
€26,20
52-wk low
€12,62
EPS
€0,91
Shares outstanding
150,61 m
No. of employees
5 k
Open
€21,95
High
€21,95
Low
€21,50
Mkt. cap
3,27 mjd
Avg. vol.
81,64 k
Volume
11,46 k
Dividend
0,83%
Quarterly dividend
€0,05
Ex-dividend date
04 Feb. 2026
P/E ratio
23,78
52-wk high
€26,20
52-wk low
€12,62
EPS
€0,91
Shares outstanding
150,61 m
No. of employees
5 k
News stories
From web sources and news partners
Profile
Schott Pharma is a provider of drug containment solutions and delivery systems for injectable drugs. Originally a division of glass manufacturer Schott AG, the company went public on the Frankfurt Stock Exchange in 2023. Headquartered in Mainz, Germany, the company operates in 14 countries. Wikipedia
About SCHOTT Pharma AG & Co KgaA
CEO-
Employees5 k
Founded01 Aug. 2022
Headquarters-
SectorHealth Care
Industry-
Last report
12 Aug. 2026
Fiscal period
Q3 2026
€0,26 / €0,26
-1,81%miss
Revenue / Est. (EUR)
281,76 m / 272,46 m
+3,41%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
247,58 m
240,19 m
247,88 m
281,76 m
Cost of goods sold
171,50 m
160,44 m
172,78 m
195,38 m
Cost of revenue
171,50 m
160,44 m
172,78 m
195,38 m
Research and development expenses
6,36 m
7,34 m
6,05 m
6,34 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
32,89 m
33,73 m
32,51 m
35,30 m
Operating expense
35,95 m
40,70 m
35,55 m
37,48 m
Total operating expenses
207,45 m
201,14 m
208,33 m
232,86 m
Operating income
40,14 m
39,05 m
39,55 m
48,90 m
Other non operating income
-61,00 k
-79,00 k
-212,00 k
-116,00 k
EBT including unusual items
41,76 m
42,04 m
40,31 m
51,23 m
EBT excluding unusual items
41,02 m
42,04 m
40,31 m
51,23 m
Income tax expense
8,09 m
8,76 m
9,17 m
12,25 m
Effective tax rate
19,37%
20,84%
22,76%
23,91%
Other operating expenses
-3,30 m
-366,00 k
-3,01 m
-4,16 m
Net income
33,56 m
33,18 m
31,01 m
38,83 m
Net profit margin
13,55%
13,81%
12,51%
13,78%
Earnings per share
0,22
0,22
0,21
0,26
Interest and investment income
2,02 m
2,33 m
1,84 m
1,96 m
Interest expense
-4,71 m
-4,00 m
-4,01 m
-3,87 m
Net interest expenses
-2,69 m
-1,67 m
-2,16 m
-1,91 m
Depreciation and amortization charges
-
-
-
-
EBITDA
56,70 m
60,46 m
61,41 m
71,14 m
Gain or loss from assets sale
-88,00 k
-48,00 k
-72,00 k
48,00 k
Upcoming events
AI content may include mistakes. Learn more
Google-programme